ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.Cancers · 2025Article
- Applications of 3D models in cholangiocarcinoma.Frontiers in oncology · 2025Review
- Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1.Human cell · 2024Article
- Leveraging Patient-Derived Organoids for Personalized Liver Cancer Treatment.International journal of biological sciences · 2024Article
- An Insight into Different Experimental Models used for Hepatoprotective Studies: A Review.Current drug discovery technologies · 2024Review
- Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3.Human cell · 2023Article
- Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.The American journal of pathology · 2022Review
- Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.Frontiers in oncology · 2022Article
- The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.International journal of molecular sciences · 2021Review
- Patient-Derived Organoids of Cholangiocarcinoma.International journal of molecular sciences · 2021Article
- Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX).NPJ breast cancer · 2021Article
- Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition.Nature communications · 2021Article
- A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient.Cancers · 2021Article
- Benefits of Zebrafish Xenograft Models in Cancer Research.Frontiers in cell and developmental biology · 2021Review
- Article
- Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines.Annals of surgical oncology · 2019Article
- Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.International journal of molecular sciences · 2019Review
- Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine.Cancers · 2019Article
- Next-Generation Liver Medicine Using Organoid Models.Frontiers in cell and developmental biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biliary tract carcinoma is a rare malignancy with multiple causes, which underlie the different genetic and molecular profiles. Cancer cell lines are affordable models, reflecting the characteristics of the tumor of origin. They represent useful tools to identify molecular targets for treatment. Here, we established and characterized from biological, molecular, and genetic point of view, an Italian intrahepatic cholangiocarcinoma cell line (ICC), the MT-CHC01. MT-CHC01 cells were isolated from a tumor-derived xenograft. Immunophenotypical characterization was evaluated both at early and after stabilization passages. In vitro biological, genetic, and molecular features were also investigated. In vivo tumorigenicity was assessed in NOD/SCID mice. MT-CHC01cells retain epithelial cell markers, EPCAM, CK7, and CK19, and some stemness and pluripotency markers, i.e., SOX2, Nanog, CD49f/integrin-α6, CD24, PDX1, FOXA2, and CD133. They grow as a monolayer, with a population double time of about 40 h; they show a low migration and invasion potential. In low attachment conditions, they are able to form spheres and to growth in anchorage-independent manner. After subcutaneous injection, they retain in vivo tumorigenicity; the expression of biliary markers as CA19-9 and CEA were maintained from primary tumor. The karyotype is highly complex, with a hypotriploid to hypertriploid modal number (3n+/-) (52 to 77 chromosomes); low level of HER2 gene amplification, TP53 deletion, gain of AURKA were identified; K-RAS G12D mutation were maintained from primary tumor to MT-CHC01 cells. We established the first ICC cell line derived from an Italian patient. It will help to study either the biology of this tumor or to test drugs both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.